Abstract
CYP3A5 genetic variants are associated with tacrolimus metabolism. Controversy remains on whether CYP3A4 increased [*1B (rs2740574), *1āG (rs2242480)] and decreased function [*22 (rs35599367)] genetic variants provide additional information. This retrospective cohort study aims to address whether tacrolimus dose-adjusted trough concentrations differ between combined CYP3A (CYP3A5 and CYP3A4) phenotype groups. Heart transplanted patients (nā=ā177, between 2008 and 2020) were included and median age was 54 years old. Significant differences between CYP3A phenotype groups in tacrolimus dose-adjusted trough concentrations were found in the early postoperative period and continued to 6 months post-transplant. In CYP3A5 nonexpressers, carriers of CYP3A4*1B or *1āG variants (Group 3) compared to CYP3A4*1/*1 (Group 2) patients were found to have lower tacrolimus dose-adjusted trough concentrations at 2 months. In addition, significant differences were found among CYP3A phenotype groups in the dose at discharge and time to therapeutic range while time in therapeutic range was not significantly different. A combined CYP3A phenotype interpretation may provide more nuanced genotype-guided TAC dosing in heart transplant recipients.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 6 print issues and online access
$259.00 per year
only $43.17 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
McCormack PL, Keating GM. Tacrolimus: in heart transplant recipients. Drugs. 2006;66:2269ā79. discussion 2280-2282
Sƶderlund C, RĆ„degran G. Immunosuppressive therapies after heart transplantation-The balance between under- and over-immunosuppression. Transplant Rev (Orlando). 2015;29:181ā9.
Adie SK, Bitar A, Konerman MC, Dorsch MP, Andrews CA, Pogue K, et al. Tacrolimus time in therapeutic range and long-term outcomes in heart transplant recipients. Pharmacotherapy. 2022;42:106ā11.
Baker WL, Steiger S, Martin S, Patel N, Radojevic J, Darsaklis K, et al. Association between time-in-therapeutic tacrolimus range and early rejection after heart transplant. Pharmacotherapy. 2019;39:609ā13.
Sirota M, Heyrend C, Ou Z, Masotti S, Griffiths E, Molina K. Impact of tacrolimus variability on pediatric heart transplant outcomes. Pediatr Transplant. 2021;25:e14043.
Uno T, Wada K, Matsuda S, Terada Y, Oita A, Kawase A, et al. Impact of the CYP3A5*1 allele on the pharmacokinetics of tacrolimus in japanese heart transplant patients. Eur J Drug Metab Pharmacokinet. 2018;43:665ā73.
Deininger KM, Vu A, Page RL, Ambardekar AV, Lindenfeld J, Aquilante CL. CYP3A pharmacogenetics and tacrolimus disposition in adult heart transplant recipients. Clin Transplant. 2016;30:1074ā81.
Gijsen VMGJ, van Schaik RH, Elens L, Soldin OP, Soldin SJ, Koren G, et al. CYP3A4*22 and CYP3A combined genotypes both correlate with tacrolimus disposition in pediatric heart transplant recipients. Pharmacogenomics. 2013;14:1027ā36.
Yu M, Liu M, Zhang W, Ming Y. Pharmacokinetics, pharmacodynamics and pharmacogenetics of tacrolimus in kidney transplantation. Curr Drug Metab. 2018;19:513ā22.
Haufroid V, Mourad M, Van Kerckhove V, Wawrzyniak J, De Meyer M, Eddour DC, et al. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics. 2004;14:147ā54.
Birdwell KA, Decker B, Barbarino JM, Peterson JF, Stein CM, Sadee W, et al. Clinical pharmacogenetics implementation consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing. Clin Pharmacol Ther. 2015;98:19ā24.
Li J, Liu S, Fu Q, Zhang Y, Wang X, Liu X, et al. Interactive effects of CYP3A4, CYP3A5, MDR1 and NR1I2 polymorphisms on tracrolimus trough concentrations in early postrenal transplant recipients. Pharmacogenomics. 2015;16:1355ā65.
Zuo X, Ng CM, Barrett JS, Luo A, Zhang B, Deng C, et al. Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients: a population pharmacokinetic analysis. Pharmacogenet Genom. 2013;23:251ā61.
Shi W-L, Tang H-L, Zhai S-D. Effects of the CYP3A4*1B genetic polymorphism on the pharmacokinetics of tacrolimus in adult renal transplant recipients: a meta-analysis. PLoS ONE. 2015;10:e0127995.
Pallet N, Jannot A-S, El Bahri M, Etienne I, Buchler M, de Ligny BH, et al. Kidney transplant recipients carrying the CYP3A4*22 allelic variant have reduced tacrolimus clearance and often reach supratherapeutic tacrolimus concentrations. Am J Transplant. 2015;15:800ā5.
Bruckmueller H, Werk AN, Renders L, Feldkamp T, Tepel M, Borst C, et al. Which genetic determinants should be considered for tacrolimus dose optimization in kidney transplantation? A combined analysis of genes affecting the CYP3A locus. Ther Drug Monit. 2015;37:288ā95.
Aouam K, Kolsi A, Kerkeni E, Ben Fredj N, Chaabane A, Monastiri K, et al. Influence of combined CYP3A4 and CYP3A5 single-nucleotide polymorphisms on tacrolimus exposure in kidney transplant recipients: a study according to the post-transplant phase. Pharmacogenomics. 2015;16:2045ā54.
Liu M, Shaver CM, Birdwell KA, Heeney SA, Shaffer CM, Van Driest SL. Composite CYP3A phenotypes influence tacrolimus dose-adjusted concentration in lung transplant recipients. Pharmacogenet Genomics. 2022;32:209ā17.
DĆ©ri M, SzakĆ”l-TĆ³th Z, Fekete F, MangĆ³ K, Incze E, Minus A, et al. CYP3A-status is associated with blood concentration and dose-requirement of tacrolimus in heart transplant recipients. Sci Rep. 2021;11:21389.
Bowton E, Field JR, Wang S, Schildcrout JS, Van Driest SL, Delaney JT, et al. Biobanks and electronic medical records: enabling cost-effective research. Sci Transl Med. 2014;6:234cm3.
Roden DM, Pulley JM, Basford MA, Bernard GR, Clayton EW, Balser JR, et al. Development of a large-scale de-identified DNA biobank to enable personalized medicine. Clin Pharmacol Ther. 2008;84:362ā9.
Doligalski CT, Liu EC, Sammons CM, Silverman A, Logan AT. Sublingual administration of tacrolimus: current trends and available evidence. Pharmacotherapy. 2014;34:1209ā19.
Rosendaal FR, Cannegieter SC, van der Meer FJ, BriĆ«t E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost. 1993;69:236ā9.
Flockhart DA, Thacker D, McDonald C, Desta Z. The flockhart cytochrome P450 drug-drug interaction table. https://drug-interactions.medicine.iu.edu/MainTable.aspx (accessed May 2022).
Center for Drug Evaluation and Research. Drug Development and Drug Interactions | Table of Substrates, Inhibitors and Inducers. FDA. 2022. https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers (accessed Mar 2023).
Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract. 2012;120:c179ā184.
Lunde I, Bremer S, Midtvedt K, Mohebi B, Dahl M, Bergan S, et al. The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients. Eur J Clin Pharmacol. 2014;70:685ā93.
Luo X, Zhu L, Cai N, Zheng L, Cheng Z. Prediction of tacrolimus metabolism and dosage requirements based on CYP3A4 phenotype and CYP3A5 * 3 genotype in Chinese renal transplant recipients. Acta Pharmacologica Sinica. 2016;37:555ā60.
van Gelder T. Drug interactions with tacrolimus. Drug Saf. 2002;25:707ā12.
Undre N, Dickinson J. Relative bioavailability of single doses of prolonged-release tacrolimus administered as a suspension, orally or via a nasogastric tube, compared with intact capsules: a phase 1 study in healthy participants. BMJ Open. 2017;7:e012252.
Funding
Support for this work is provided by funding from Vanderbilt University Medical Centerās BioVU (with data stored in Research Electronic Data Capture), which are supported by institutional funding and by the Clinical and Translational Science Award UL1 TR000445 from the National Institutes of Healthās National Center for Advancing Translational Sciences. ML is supported by Vanderbiltās Maternal and Pediatric Precision in Therapeutics Center of Excellence of the National Institute of Child Health and Human Development project grant P50HD106446. SLV was supported by the National Institute of General Medical Sciences research project grant 1 R01 GM132204.
Author information
Authors and Affiliations
Contributions
ML, SH, CLA, KMD, JL, KLS and SLV wrote the manuscript and interpreted results. ML and SLV designed the research study. ML and SD extracted data. ML analyzed data.
Corresponding author
Ethics declarations
Competing interests
ML, SH, CLA, JL, KHS and SLV declare no relevant conflicts of interest. KMD was an employee of University of Colorado at the time of this work and is currently an employee of Amgen Pharmaceuticals. SLV was an employee of Vanderbilt University Medical Center at the time of this work and is currently an employee of the National Institutes of Health, Office of the Director, All of Us Research Program.
Additional information
Publisherās note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Liu, M., Hernandez, S., Aquilante, C.L. et al. Composite CYP3A (CYP3A4 and CYP3A5) phenotypes and influence on tacrolimus dose adjusted concentrations in adult heart transplant recipients. Pharmacogenomics J 24, 4 (2024). https://doi.org/10.1038/s41397-024-00325-2
Received:
Revised:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41397-024-00325-2